StellarCube selected for Seoul Startup Hub's Boston Biohealth Global Expansion Program 2026
Defining PainCube's US market entry strategy through partnerships with local hospitals and industry
StellarCube, an AI healthcare company, announced on 30 July that it has been selected for the Seoul Startup Boston Biohealth Global Expansion Program 2026, operated by the Seoul Business Agency (SBA).
StellarCube is taking part with PainCube, its AI-based pain management solution, at the center of its participation. Through the program, the company plans to deepen its understanding of the US healthcare market and medical device regulation, identify opportunities for clinical and technical validation and business cooperation with local hospitals and companies, and define a concrete market entry strategy for PainCube.
The program is open to bio and healthcare companies based in Seoul that are preparing to enter the US market or expand globally. CIC (Cambridge Innovation Center), an innovation ecosystem organization in Boston and Cambridge, takes part in running it. The official program name is the Seoul Startup Boston Biohealth Global Expansion Program 2026.
Its main goals are to help participating companies build networks in the US, understand the local market and regulatory environment, assess the feasibility of a US proof of concept, and define a market entry roadmap. It also supports outreach to local institutions and meeting preparation based on each company's business direction and cooperation needs.
StellarCube plans to use the entire program to raise PainCube's readiness for the US market. Specifically, it will analyze the US healthcare market and medical device regulatory environment and assess PainCube's applicability and market entry direction there. It will also review opportunities for clinical collaboration and proof-of-concept work through meetings with hospitals, research institutes and healthcare companies, and build a partner network for sustained cooperation in the US market.
Staged support, from online sessions to the Boston program
The program runs in stages: online education, tailored mentoring, the on-site program in Boston, and follow-up.
The first stage, online group sessions, takes place on 18 and 19 August. The sessions cover the US healthcare market and regulatory environment, global networking and outreach to local stakeholders, and effective business communication strategies for the US market.
One-to-one online mentoring for each participating company follows. The mentoring provides tailored coaching and feedback on US market entry and business strategy, communication with local institutions, and preparation for partner meetings. Ahead of the on-site program, StellarCube will research potential partner organizations in the Boston area and define the cooperation agenda and meeting direction for each. From 24 August to 9 October, one-to-one sessions with CIC will also review how the program is progressing.
The on-site program in Boston is scheduled for 12 to 16 October. StellarCube will take part in panels and roundtables with local founders, closed-door pitching and feedback sessions with venture capital firms and experts, a Venture Café demo event, and business matching meetings with local institutions and companies.
At the demo event held at Venture Café Cambridge in particular, the company will introduce PainCube's technology and potential applications to prospective partner organizations, experts and investors. The event is a networking occasion where startups present their technology and business ideas and discuss possible collaboration with members of the local innovation ecosystem.
CIC will continue follow-up reviews for three months after the on-site schedule ends. During that period StellarCube will review progress in discussions with business matching organizations, additional partnership opportunities, US market entry preparations and relationship building with prospective customers, and continue follow-up discussions.
Building the basis for US clinical work and commercialization
PainCube is software as a medical device that uses AI to analyze high-resolution biosignals and clinical data from patients, quantify pain, and predict the likelihood of pain occurring in advance, supporting clinical decision-making.
StellarCube is pursuing research, development and clinical validation of PainCube with medical and research institutions in Korea and abroad, including Johns Hopkins University and Korea University Anam Hospital. In April 2026 it also established StellarCube USA, a local subsidiary in the United States, laying the groundwork for clinical collaboration and commercialization there.
Rather than simply presenting existing research results, the program will focus on defining the regulatory, clinical, proof-of-concept and business cooperation tasks required for PainCube to reach actual US clinical settings.
Jinseob Noh, CEO of StellarCube, said: "This program will be an opportunity to go beyond introducing PainCube's technology to the US market and to examine, concretely and with local experts and partners, the regulatory, clinical and commercialization requirements for applying it in real clinical settings."
He added: "Through online mentoring and business matching in Boston we will identify opportunities for clinical and proof-of-concept collaboration with US medical institutions, and expand partnerships with local hospitals, research institutes and healthcare companies. We will continue these discussions after the program and turn them into tangible results for PainCube's entry into the US market."
StellarCube develops healthcare solutions based on AI and data technology. Building on data processing capabilities that turn unstructured data into analyzable information, the company is developing PainCube, conducting joint research with medical and research institutions in Korea and abroad, and pursuing global software as a medical device approval and entry into the digital healthcare market.